Engineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression.

ABSTRACT: Islet transplantation has been established as a viable treatment modality for type 1 diabetes. However, the side effects of the systemic immunosuppression required for patients often outweigh its benefits. Here, we engineer programmed death ligand-1 and cytotoxic T lymphocyte antigen 4 immunoglobulin fusion protein-modified mesenchymal stromal cells (MSCs) as accessory cells for islet cotransplantation. The engineered MSCs (eMSCs) improved the outcome of both syngeneic and allogeneic islet transplantation in diabetic mice and resulted in allograft survival for up to 100 days without any systemic immunosuppression. Immunophenotyping revealed reduced infiltration of CD4⁺ or CD8⁺ T effector cells and increased infiltration of T regulatory cells within the allografts cotr

SUBMITTER: Wang X 

PROVIDER: S-EPMC9307254 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature